Nanexa AB (OSTO:NANEXA) Research & Development: kr12.92 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NANEXA Nanexa AB OSTO:NANEXA
56 GF Score
Price kr4.80
GF Value kr2.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Nanexa AB Research & Development?

Nanexa AB OSTO:NANEXA +6.31% 56 Research & Development is kr12.92 Mil as of Jun. 2026. GuruFocus rates OSTO:NANEXA with a GF Score™ of 56/100 and a GF Value™ of kr2.00 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nanexa AB's Research & Development for the three months ended in Jun. 2026 was kr4.03 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was kr12.92 Mil.

Nanexa AB  (OSTO:NANEXA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nanexa AB Research & Development Related Terms

Nanexa AB Research & Development Historical Data

* Premium members only.

The historical data trend for Nanexa AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanexa AB Research & Development Chart

Nanexa AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.70 23.77 27.71 16.53 13.64

Nanexa AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.48 3.02 2.87 3.00 4.03
OSTO:NANEXA
56GF Score
Nanexa AB OSTO:NANEXA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanexa AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr12.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr12.92 Mil mean?
Nanexa AB (OSTO:NANEXA) has a Research & Development of kr12.92 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Nanexa AB and its competitors.
Is Nanexa AB's Research & Development too high?
Nanexa AB's current Research & Development is kr12.92 Mil. Overall, Nanexa AB has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's Research & Development compare to ZTS?
Nanexa AB's Research & Development of kr12.92 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nanexa AB and its competitors. Nanexa AB's current Research & Development is kr12.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (OSTO:NANEXA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.00, compared to a current price of kr4.80 — trading 140% above its estimated fair value. The current Research & Development is kr12.92 Mil. Nanexa AB's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nanexa AB (OSTO:NANEXA), the current Research & Development is kr12.92 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanexa AB (OSTO:NANEXA) Overvalued in 2026?

Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued. The current stock price of kr4.80 is trading 140% above its estimated GF Value™ of kr2.00. GuruFocus considers Nanexa AB to be Significantly Overvalued.

Key valuation signals for OSTO:NANEXA:

  • Research & Development: kr12.92 Mil
  • GF Value™: kr2.00 vs. price of kr4.80 (140% above fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the OSTO:NANEXA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanexa AB Business Description

Other Exchanges 40M:Germany
Address Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
56GF Score

Get the complete analysis for OSTO:NANEXA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.80
Price
kr2.00
GF Value